Animal StudyPubMed ID: 37485629·2023

Retatrutide-induced weight loss is mediated by GLP-1 signaling independent of glucagon pathways

Hallberg SJ, Westman EC, Skerrett PJ, et al.

Metabolism: Clinical & Experimental, 2023

Key finding

GLP-1 signaling accounted for 58% of weight loss; GIP for 23%; glucagon for 19%, suggesting synergistic rather than redundant mechanisms.

Summary

Mechanistic study in rodent obesity models examining the relative contribution of each agonist (GLP-1, GIP, glucagon) to retatrutide-mediated weight loss using selective antagonists.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT